您的购物车当前为空
别名 TG-101348 hydrochloride hydrate, SAR 302503 hydrochloride hydrate
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) 是一种选择性的,ATP 竞争性和具有口服活性的JAK2抑制剂,对于JAK2和JAK2V617F 激酶的IC50均为 3 nM。它可诱导癌细胞凋亡,可研究骨髓增生性疾病。

Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) 是一种选择性的,ATP 竞争性和具有口服活性的JAK2抑制剂,对于JAK2和JAK2V617F 激酶的IC50均为 3 nM。它可诱导癌细胞凋亡,可研究骨髓增生性疾病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 197 | In stock | |
| 5 mg | ¥ 413 | In stock | |
| 10 mg | ¥ 578 | In stock | |
| 25 mg | ¥ 782 | In stock | |
| 50 mg | ¥ 985 | In stock | |
| 100 mg | ¥ 1,230 | In stock | |
| 500 mg | ¥ 3,120 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 637 | In stock |
Fedratinib hydrochloride hydrate 相关产品
| 产品描述 | Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor. |
| 靶点活性 | FLT3:15 nM, RET:48 nM, JAK2 (V617F):3 nM, JAK2:3 nM |
| 别名 | TG-101348 hydrochloride hydrate, SAR 302503 hydrochloride hydrate |
| 分子量 | 615.61 |
| 分子式 | C27H40Cl2N6O4S |
| CAS No. | 1374744-69-0 |
| Smiles | O.Cl.Cl.Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C |
| 密度 | no data available |
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 120 mg/mL (194.92 mM), Sonication is recommended. H2O: 97 mg/mL (157.56 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (6.5 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容